Gene Therapies for Cancer Treatment Market Advancements and Opportunities

Gene Therapies for Cancer Treatment Market Size, Key Players with Growth and Dynamics

The global gene therapies for cancer treatment market size is calculated at USD 8.28 billion in 2024, grew to USD 11.59 billion in 2025, and is projected to reach around USD 238.77 billion by 2034. The market is expanding at a CAGR of 39.94% between 2025 and 2034.

The gene therapies for cancer treatment market is primarily driven by the increasing demand for targeted treatment and growing research activities. Government organizations provide funding for the research and manufacturing of gene therapies as well as support the precision oncology field. Artificial intelligence (AI) revolutionizes the development of gene therapies, driving precision and accuracy. Advances in genomic technologies present future opportunities for market growth.

Key Takeaways

• Gene therapies for cancer treatment sector pushed the market to USD 8.28 billion by 2024.
• Long-term projections show USD 238.77 billion valuation by 2034.
• Growth is expected at a steady CAGR of 39.94% in between 2025 to 2034.
• North America held a major revenue share of approximately 42% in the market in 2024.
• Asia-Pacific is expected to witness the fastest growth during the predicted timeframe.
• By therapy type/modality, the CAR-T cell therapy segment dominated the gene therapies for cancer treatment market with a share of approximately 35% in 2024.
• By therapy type/modality, the oncolytic virus therapy segment is expected to witness the fastest growth in the market over the forecast period.
• By cancer type/indication, the hematological cancers segment accounted for the highest revenue share of approximately 42% in the market in 2024.
• By cancer type/indication, the melanoma & skin cancers segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By vector/delivery method, the lentiviral vectors segment registered its dominance over the global market with a share of approximately 30% in 2024.
• By vector/delivery method, the non-viral delivery segment is expected to show the fastest growth in the gene therapies for cancer treatment market over the forecast period.
• By treatment setting/administration, the hospital/oncology centers segment held the largest revenue share of approximately 60% in the market in 2024.
• By treatment setting/administration, the home/outpatient self-administered programs segment is expected to expand rapidly in the market in the coming years.
• By distribution channel, the hospital pharmacies/infusion centers segment held a dominant revenue share of approximately 55% in the market in 2024.
• By distribution channel, the direct-to-patient/home delivery segment is expected to grow with the highest CAGR in the market during the studied years.

Quick Facts Table

What are Gene Therapies for Cancer Treatment?

The gene therapies for cancer treatment market is fueled by rising incidence of hematologic and solid tumors, advances in cell and gene therapy platforms, increasing regulatory approvals, and growing investment in precision oncology. It involves the use of genetic material to modify a patient’s cells to treat or prevent cancer. Approaches include viral vector-mediated gene delivery, CAR-T (chimeric antigen receptor T-cell) therapy, TCR therapy, oncolytic viruses, RNA-based therapies, and CRISPR-based editing. These therapies can target specific cancer mutations, enhance immune response, or sensitize tumors to other treatments.

Gene Therapies for Cancer Treatment Market Outlook

• Industry Growth Overview: The market is expected to experience robust growth in the coming years due to advances in gene editing techniques, such as CRISPR and digital PCR, and new delivery methods for higher precision. People are becoming increasingly aware of targeted and personalized medicines, which is promoting market growth.
• Sustainability Trends: Researchers are currently studying the impact of cell and gene therapy (CGT) manufacturing on the environment. They are making constant efforts to select an environmentally friendly gene therapy production process.
• Major Investors: Private equity firms and venture capitalists provide funding to CGT manufacturers to deliver products faster. Alliance for Cancer Gene Therapy and Cell and Gene Therapy Catapult are private organizations that invest in biotech companies.
• Startup Ecosystem: The startup ecosystem for gene therapy is maturing, with increasing venture capital investments and the growing need to drive innovation in gene therapies. ImmunoACT, Castle Creek Biosciences, and Frontera Therapeutics are some of the major startups of gene therapies.

How Can AI Improve the Gene Therapies for Cancer Treatment Market?

AI can improve the development of gene therapies using advanced computational methods, leading to more effective and stable therapeutics. AI and machine learning (ML) algorithms can analyze vast amounts of patient data and identify new biomarkers to assist tumor screening, detection, diagnosis, treatment, and prognosis prediction. They can allow researchers to develop efficacious gene therapies with reduced adverse effects. They can enable healthcare professionals to make proactive clinical decisions.

Tempus, an AI-based precision medicine developer, has generated the xT Platform to increase personalized therapeutic opportunities for cancer patients.

Gene Therapies for Cancer Treatment Market: Investment Portfolio

• In September 2025, Integra Therapeutics received funding of €10.7 million (USD 12.6 million) from the European Innovation Council Fund and CDTI Innvierte program to accelerate the technical development of its find and cut-and-transfer (FiCAT) gene writing platform.
• In March 2025, Equity Gap invested £700,000 in Lentitek Ltd. to accelerate the development and commercialization of its groundbreaking viral vector technology for next-gen cancer treatments.
• In September 2024, Vironexis Biotherapeutics announced that it received $26 million in funding from Drive Capital and Future Ventures to develop off-the-shelf, single-dose gene therapies to treat rare cancer types more effectively, more safely, and with more durability.
• In July 2024, Taiba invested $12 million in Immuneel Therapeutics to advance CAR-T cell research and develop the first Phase 2 trial for targeting B-cell malignancies.

Licensed Gene Therapies for Cancer Treatment

Segmental Insights

Which Therapy Type/Modality Segment Dominated the Market?

By therapy type/modality, the CAR-T cell therapy segment held a dominant presence in the gene therapies for cancer treatment market with a share of approximately 35% in 2024, due to the immuno-modulatory effect of CAR-T cells and high specificity. Human T-cells are genetically engineered to express the CAR and are administered into the body to attack cancer cells. They provide long-term effects, preventing disease recurrence. The 2025 Nobel Prize for Physiology/Medicine for T-cell research further lays the foundation for a new field of research and spurs the development of novel treatments.

By therapy type/modality, the oncolytic virus therapy segment is expected to grow at the fastest CAGR in the market during the forecast period. Oncolytic viruses are a type of immunotherapy that uses viruses to infect and destroy cancer cells. They replicate rapidly, destroy the cells by breaking them open, and expose the cell’s contents to the immune system. The U.S. FDA has approved T-VEC, an oncolytic virus, for the treatment of metastatic melanoma.

How the Hematological Cancers Segment Dominated the Market?

By cancer type/indication, the hematological cancers segment held the largest revenue share of approximately 42% in the gene therapies for cancer treatment market in 2024, due to the rising prevalence of blood cancers and the availability of licensed therapeutics. Gene therapy offers hope for patients with blood cancers resistant to conventional therapies. Leukemia is estimated to account for 7.1% of all malignancies in men and 6.4% in women in India. Ongoing efforts are made to develop innovative gene therapy that can kill any type of blood cancer cell.

By cancer type/indication, the melanoma & skin cancers segment is expected to grow with the highest CAGR in the market during the studied years. Gene therapy has proved to be vital for treating melanoma by directly targeting the genes involved in causing skin cancer. The American Cancer Society estimated that about 104,960 new melanomas will be diagnosed in 2025 in the U.S. Melanoma is generally caused by long-term exposure to UV radiation, a weakened immune system, and family history.

Why Did the Lentiviral Vectors Segment Dominate the Market?

By vector/delivery method, the lentiviral vectors segment contributed the biggest revenue share of approximately 30% in the gene therapies for cancer treatment market in 2024, due to the large genetic capacity of lentiviral vectors and the ability to transduce dividing and non-dividing cells. Lentiviral vectors have garnered significant attention as vehicles for gene therapy due to their safety and stability. They are also more efficient in delivering the genetic material. Improved bioprocessing methods are developed for customized lentivirus production.

By vector/delivery method, the non-viral delivery segment is expected to expand rapidly in the market in the coming years. Non-viral vectors eliminate the chance of viral infections in humans. Some common examples of non-viral vectors include lipid nanoparticles, exosomes, cationic polymers, hydrogels, and inorganic nanoparticles. They offer several advantages, such as flexible chemical composition, high DNA loading, and easily modulated topology.

What Made Hospital/Oncology Centers the Dominant Segment in the Market?

By treatment setting/administration, the hospital/oncology centers segment accounted for the highest revenue share of approximately 60% in the gene therapies for cancer treatment market in 2024, due to the availability of favorable infrastructure and the presence of skilled professionals. Hospitals have skilled professionals from various departments, providing multidisciplinary expertise to patients. Suitable capital investments enable hospitals and oncology centers to adopt advanced therapeutics for cancer. The U.S. is home to 73 NCI-designated cancer centers.

By treatment setting/administration, the home/outpatient self-administered programs segment is expected to witness the fastest growth in the market over the forecast period. Healthcare professionals provide personalized treatment by delivering gene therapy to patients in the comfort of their homes. Outpatient programs are conducted to allow patients to return to their work without impacting their productivity. According to a recent study, out of 70% of study participants who received CAR-T cell therapy on an outpatient basis, one-quarter never required hospitalization. Future trends may involve the development of self-administration kits for gene therapy.

Which Distribution Channel Segment Led the Market?

By distribution channel, the hospital pharmacies/infusion centers segment led the gene therapies for cancer treatment market with a share of approximately 55% in 2024, due to the increasing number of hospital admissions and favorable regulatory support. Hospital pharmacies and infusion centers possess the desired facility for the reception, storage, reconstitution, administration, and waste disposal of gene therapies. Patients prefer purchasing gene therapies from hospital pharmacies due to suitable reimbursement policies.

By distribution channel, the direct-to-patient/home delivery segment is expected to show the fastest growth over the forecast period. Patients usually prefer gene therapy administration at their homes. Several private healthcare organizations provide at-home services to patients. However, this practice is still in its experimental stage, and healthcare professionals are determining the standard practice for home delivery of gene therapies.

Regional Analysis

Which Factors Govern the Gene Therapies for Cancer Treatment Market in North America?

North America dominated the global market with a share of approximately 42% in 2024. The availability of state-of-the-art research and development facilities, the presence of key players, and favorable government support are the major factors that govern market growth in North America. Government and private organizations provide funding for the development of innovative gene therapy. They also launch initiatives to create awareness among the general public about personalized medicines.

U.S. Market Trends

Numerous U.S.-based companies like Bristol Myers Squibb, Moderna, and Kite Pharma develop and market gene therapy products for cancer patients in the U.S. The U.S. conducts the highest number of clinical trials in the world. Out of the total 1,543 trials related to gene therapies for cancer, about 803 are registered in the U.S. as of October 2025.  As of 2023, the U.S. FDA has approved a total of 8 gene therapy products for oncology treatment.

Canada Market Trends

Health Canada regulates the approval of gene therapy products under the Canadian Food and Drugs Act, accounting for 10 gene therapy products. Of these, 6 are CAR-T cell therapies indicated for different cancer types. The Canadian Cancer Society estimates that 2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. The Canadian government also actively supports gene therapy development and manufacturing. It invested over $2.2 billion from March 2020 to July 2024 to strengthen Canada’s domestic biomanufacturing.

Why is Asia-Pacific the Fastest-Growing Region in the Market?

Asia-Pacific is expected to host the fastest-growing gene therapies for cancer treatment market in the coming years. Countries like China, India, Japan, and South Korea are emerging as prominent global manufacturing hubs for gene therapy products due to favorable infrastructure and an affordable workforce. Research institutes and biotech companies conduct seminars, workshops, and conferences to share the latest updates about gene therapy and genomic technologies. The rising prevalence of cancer and the growing geriatric population foster market growth.

Country-level Investments & Funding Trends

• New South Wales: In June 2025, the New South Wales (NSW) government announced an investment of A$20.7 million ($13.39 million) in access to CAR-T cell therapies for individuals suffering from rare blood cancers.
• United Kingdom: The UK government announced an investment of £30 million in the UK RNA Biofoundry, a specialized facility, to support the development of new RNA therapies.
• Abu Dhabi: The Department of Health – Abu Dhabi (DOH) and the Authority of Social Contribution – Ma’an awarded AED19 million to support advancements in groundbreaking fields, such as cell and gene therapies and precision medicine.

Value Chain Analysis – Gene Therapies for Cancer Treatment Market

R&D

The latest research activities for gene therapy include the development of innovative gene therapies with enhanced efficacy. Researchers also develop novel delivery systems for a targeted approach.

Key Players: Intellia Therapeutics, Kite Pharma, Inc., and CRISPR Therapeutics.

Clinical Trials & Regulatory Approval

Clinical trials are research studies that help healthcare professionals find out whether a gene therapy approach is safe for people. Regulatory agencies approve gene therapy products based on the results of clinical trials.

Key Players: Shenzhen SiBiono GeneTech Co., Ltd., GlaxoSmithKline, and Celgene.

Patient Support & Services

Patient support & services refers to conducting insurance coverage reviews, assisting with prior authorizations and appeals, and offering support through personalized care.

Top Companies & Their Offerings

The major companies in the gene therapies for cancer treatment market include:

• Novartis AG: Novartis is a Swiss multinational pharmaceutical company that specializes in individualized CAR-T cell therapy using a patient’s immune system to fight certain types of cancers.
• Bristol Myers Squibb: The American multinational company actively evaluates methods to optimize CAR-T cell design and manufacturing to advance next-generation cell therapies for cancer.
• Adaptimmune: Adaptimmune is a clinical-stage biopharmaceutical company that focuses on the development of novel immunotherapy products for cancer patients.
• Moderna: Moderna is an American pharmaceutical and biotechnology company that develops the use of mRNA in immune-oncology that may activate the body’s immune system to attack tumor cells.
• CRISPR Therapeutics: The Swiss-American biotech company develops a portfolio of CAR-T cell product candidates using gene editing technology. Its CASGEVY is the first FDA-approved gene therapy for cancer.

Other Companies

• Immatics
• Legend Biotech
• Celyad Oncology
• BioNTech
• Editas Medicine
• Astellas Pharma
• Kite Pharma
• Allogene Therapeutics
• OncoImmune
• Takeda
• Sangamo Therapeutics
• Beam Therapeutics
• Charles River Laboratories

Recent Developments

• In September 2025, Stanford Medicine researchers developed an AI tool, CRISPR-GPT, to help scientists better plan gene-editing experiments. The AI tool can generate designs, analyze data, and troubleshoot design flaws, expediting the gene editing process.
• In April 2025, researchers from Wuhan University identified the mitochondrial protein TRAP1 as a key player in CRC’s defenses and disrupted its gene by developing an advanced oral CRISPR-Cas9 delivery system. This system navigates the gastrointestinal barriers to target tumors, triggering the destruction of cancer cells and activating immune responses.

Segments Covered in the Report

By Therapy Type/Modality

• CAR-T Cell Therapy
• Oncolytic Virus Therapy
• TCR (T-cell Receptor) Therapy
• Gene Editing/CRISPR-based Therapies
• RNA-based Gene Therapies (siRNA/mRNA)
• Other/Combination Approaches

By Cancer Type/Indication

• Hematological Cancers
• Melanoma & Skin Cancers
• Solid Tumors
• Prostate & Genitourinary Cancers
• Other Rare/Pediatric Cancers

By Vector/Delivery Method

• Lentiviral Vectors
• Non-viral Delivery
• Adenoviral/Adeno-Associated Viral (AAV) Vectors
• Retroviral Vectors
• Other/Hybrid Delivery Approaches

By Treatment Setting

• Hospital/Oncology Centers
• Home/Outpatient Self-administered Programs
• Specialty Cell & Gene Therapy Clinics
• Research & Clinical Trial Centers

By Distribution Channel

• Hospital Pharmacies/Infusion Centers
• Direct-to-Patient/Home Delivery
• Specialty Pharmacies/Biotech Distributors
• Other (Clinical Trial Supply Channels)

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait